secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2023-05-30T23:59:59+00:00
Accession:  0001104659-23-066171
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio dismisses auditor Withum, appoints EY; material weakness triggered restatement
--------------------------------------------------------------------------------

- Withum dismissed as auditor effective May 25, 2023; EY appointed for fiscal 2023.
- Withum's 2022 audit report included a going-concern explanatory paragraph.
- Material weakness in internal controls over R&D expense classification led to restatement of 2022 quarterly financials.
- No disagreements with Withum on accounting principles or practices.
- Restatement affected three months ended March 31, 2022, and subsequent quarters through September 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465923066171/0001104659-23-066171-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465923066171/tm2317351d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-066171

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer